1. What is the current size of the infectious disease diagnostic market?
Our proprietary research values the global infectious disease diagnostics market at USD 26.58 billion in 2025, with a projected CAGR of 9.7% to reach USD 42.20 billion by 2030.
+1 2315155523
Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.
At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.
Research Analyst


The global infectious disease diagnostics market represents one of the most dynamic and socially critical segments of the broader in vitro diagnostics (IVD) industry. Our proprietary primary research and expert interview findings value the market at USD 26.58 billion in 2025, with a projected trajectory to reach USD 42.20 billion by 2030, expanding at a robust 9.7% CAGR. This growth is not merely a pandemic-era anomaly but a structural realignment fueled by the increasing global burden of infectious diseases, heightened demand for rapid and accurate pathogen detection, and continuous innovation in molecular and point-of-care (POC) technologies.
The market encompasses a diverse array of products, technologies, and testing settings, serving hospitals, diagnostic laboratories, academic research institutes, and public health agencies. While laboratory-based testing remains the backbone of clinical decision-making, the shift toward decentralized, near-patient, and home-based testing is accelerating, reshaping procurement patterns and competitive dynamics. Our analysis indicates that the reagents, kits, and consumables segment commanded the majority of revenue share in 2024, a trend we expect to persist as test volumes rise globally.
| Metric | Value |
|---|---|
| Base Year (2025) Market Size | USD 26.58 Billion |
| Forecast Year (2030) Market Size | USD 42.20 Billion |
| CAGR (2025–2030) | 9.7% |
| Largest Product Segment | Reagents, Kits & Consumables |
| Fastest-Growing Technology | Molecular Diagnostics (PCR/NGS) |
| Dominant Testing Setting | Laboratory-Based Testing |
| Largest Regional Market | North America |
| Fastest-Growing Region | Asia Pacific |
The infectious disease diagnostics market is propelled by a confluence of demographic, epidemiological, and technological factors. Our primary research with industry stakeholders highlights the following key dynamics:
Drivers:
Restraints:
Opportunities:
The market is segmented by technology, product, test type, sample type, disease, and end user. Our analysis reveals clear leaders and fast-growing segments that inform strategic priorities.
By Technology: Immunodiagnostics held the largest share in 2024, driven by widespread use in point-of-care testing and continuous innovation in antigen/antibody assays. However, molecular diagnostics (PCR, NGS, isothermal amplification) is the fastest-growing segment, propelled by the need for high-sensitivity detection, syndromic testing panels, and AMR surveillance. Clinical microbiology and DNA sequencing are also gaining traction, particularly in hospital and reference laboratory settings.
By Product & Service: Reagents, kits, and consumables dominate revenue due to recurring usage and the expansive menu of tests available. Instruments are expected to grow at the fastest CAGR, fueled by automation and high-throughput testing adoption. Software and services are increasingly important for data management and integration with digital health platforms.
By Testing Setting: Laboratory-based testing remains the primary setting, supported by the rising incidence of infectious diseases and growing automation. Point-of-care (POC) testing is the fastest-growing segment, driven by the demand for rapid results in emergency rooms, urgent care centers, and remote settings. Home testing and self-collection kits are emerging as disruptive forces, particularly for STIs and respiratory infections.
By End User: Hospitals held the largest revenue share in 2024, reflecting their role as primary diagnostic hubs. Diagnostic laboratories are growing significantly, supported by infrastructure enhancements and the outsourcing of specialized testing. Academic research institutes contribute to innovation and clinical trials.
| Segment | Dominant Category (2024) | Fastest-Growing Category |
|---|---|---|
| Technology | Immunodiagnostics | Molecular Diagnostics |
| Product | Reagents, Kits & Consumables | Instruments |
| Testing Setting | Laboratory-Based | Point-of-Care |
| End User | Hospitals | Diagnostic Laboratories |
North America remains the largest regional market, accounting for an estimated 39.5% revenue share in 2025, driven by high healthcare expenditure, advanced diagnostic infrastructure, and a high prevalence of infectious diseases. The U.S. is the single largest country market, supported by favorable reimbursement for many tests and rapid adoption of innovative technologies. Europe follows, with robust demand from Germany, the UK, France, and Italy, though growth is tempered by cost-containment measures and varying reimbursement landscapes.
Asia Pacific is the fastest-growing region, expected to register the highest CAGR through 2030. This growth is underpinned by a large and aging population, increasing healthcare spending, government initiatives to expand diagnostic access, and rising awareness. Local manufacturing, such as the launch of Africa's first domestically produced mpox test kits in Morocco, signals a broader trend of regional capacity building. Latin America and the Middle East & Africa offer long-term potential but face challenges related to infrastructure, funding, and regulatory maturity.
| Region | 2025 Revenue Share (Est.) | Growth Outlook (CAGR 2025–2030) |
|---|---|---|
| North America | 39.5% | Moderate (6–8%) |
| Europe | 26.0% | Moderate (5–7%) |
| Asia Pacific | 25.0% | High (11–13%) |
| Latin America | 6.0% | Moderate (7–9%) |
| Middle East & Africa | 4.0% | Moderate-to-High (8–10%) |
The infectious disease diagnostics market is highly competitive, characterized by the presence of diversified global corporations and specialized niche players. Leading companies leverage their broad portfolios, R&D capabilities, and distribution networks to maintain market position. Strategic activities such as acquisitions, product launches, and partnerships are intensifying as companies seek to expand point-of-care offerings and molecular testing menus.
Key players include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, bioMérieux, Danaher (Cepheid, Beckman Coulter), Becton Dickinson, Siemens Healthineers, Bio-Rad Laboratories, QIAGEN, Hologic, Illumina, and Grifols. These companies are actively pursuing growth through:
These developments underscore the competitive thrust toward rapid, decentralized, and highly accurate diagnostic solutions.
The infectious disease diagnostics value chain spans raw material suppliers, component manufacturers, instrument and reagent producers, distributors, and end users. Critical components include antibodies, antigens, enzymes, nucleotides, and specialized plastics and membranes. The supply chain is global but has faced disruptions and heightened scrutiny following the COVID-19 pandemic, prompting manufacturers to diversify sourcing and increase inventory buffers.
Reagents and kits, the largest product segment, rely on biological raw materials that are subject to quality variability and regulatory oversight. The instruments segment, while smaller in revenue, is capital-intensive and drives recurring reagent sales. Software and services are increasingly integral for data integration, remote monitoring, and predictive analytics. Our primary research indicates that supply chain resilience and cost management are top priorities for procurement executives, with a growing emphasis on regional manufacturing to mitigate geopolitical and logistical risks.
The infectious disease diagnostics market presents several high-growth white spaces for investors and incumbents:
| Opportunity Area | Market Potential | Key Success Factors |
|---|---|---|
| POC Molecular Testing | High | Simplicity, speed, and cost-effectiveness |
| At-Home/Self-Testing | High | Regulatory clarity, consumer education, privacy |
| AI & Data Analytics | Medium-High | Integration with existing workflows, validation |
| Emerging Markets | High | Local partnerships, affordability, infrastructure |
While infectious disease diagnostics are not a homogeneous traded commodity, trade flows in diagnostic reagents, instruments, and kits are significant. According to official trade statistics, the United States, Germany, China, and the Netherlands are among the largest exporters of IVD products, while the U.S., China, Germany, and Japan are major importers. The global nature of the supply chain means that trade policies, tariffs, and logistics disruptions can impact pricing and availability. Our primary research suggests that manufacturers are increasingly pursuing nearshoring and regional production to enhance supply security. For example, QIAGEN's new facility in Spain and local manufacturing initiatives in Africa reflect this trend. Supplier dynamics are characterized by a mix of large multinationals and specialized component suppliers, with strategic partnerships and long-term contracts common to ensure quality and continuity.
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 9.7% from 2020-2034 |
| Segmentation |
|
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
| Stakeholder Role | Interview Share (%) |
|---|---|
| Procurement Director | 30% |
| Laboratory Director | 25% |
| R&D Manager | 20% |
| Hospital Administrator | 15% |
| Public Health Official | 10% |
| Company Type | Representation (%) |
|---|---|
| IVD Reagent & Kit Manufacturers | 40% |
| Instrument OEMs | 25% |
| Diagnostic Service Providers | 20% |
| Software & Analytics Vendors | 10% |
| Public Health & Research Institutes | 5% |
Our proprietary research values the global infectious disease diagnostics market at USD 26.58 billion in 2025, with a projected CAGR of 9.7% to reach USD 42.20 billion by 2030.
North America holds the largest revenue share, estimated at 39.5% in 2025, driven by advanced healthcare infrastructure and high testing volumes.
Key drivers include the rising prevalence of infectious diseases, government funding for diagnostic programs, and technological advancements in molecular and point-of-care testing.
Molecular diagnostics is the fastest-growing technology segment, while point-of-care testing is the fastest-growing testing setting, expected to register the highest CAGR through 2030.
Leading companies include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, bioMérieux, Danaher, Becton Dickinson, Siemens Healthineers, Bio-Rad Laboratories, QIAGEN, and Hologic.